Shame, Shame, Shame

Howard Richman, the former vice president of Biopure, is heading to jail, reports the Associated Press. During a complaint by Securities and Exchange Commission that accused Biopure executives of misleading their investors about their synthetic blood product's chances of being approved, Richman instructed his lawyer to say that he had terminal colon cancer — which he does not have. Richman pled guilty to obstruction of justice and was sentenced to three years in prison.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.